Rescuing protein conformation: Prospects for pharmacological therapy in cystic fibrosis

Journal of Clinical Investigation

Volumn 110, Issue 11, 2002, Pages 1591-1597

  Gelman, Marina S ^a   Kopito, Ron R ^b  

^a Pharmaceutical Product Development   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUTYRIC ACID; CHAPERONE; PROTEASOME; TRANSMEMBRANE CONDUCTANCE REGULATOR;

BIOGENESIS; CYSTIC FIBROSIS; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; WILD TYPE;

EID: 0036896021     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI0216786     Document Type: Review

References (57)

1. Kerem, B.-S., et al. 1989. ldentification of the cystic fibrosis gene: Genetic analysis. Science. 245:1073-1080.
2. Welsh, M.J., and Smith, A.E. 1993. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 73:1251-1254.
3. Wine, J.J. 1999. The genesis of cystic fibrosis lung disease. J. Clin. Invest. 103:309-312.
4. Kopito, R.R. 1999. Biosynthesis and degradation of CFTR. Physiol. Rev. 79(Suppl.):S167-S173.
5. Kleizen, B., Braakman, I., and de Jonge, H.R. 2000. Regulated trafficking of the CFTR chloride channel. Eur. J. Cell Biol. 79:544-556.
6. Riordan, J.R., et al. 1989. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science. 245:1066-1073.
7. Karcner, N., Augustinas, O., Jensen, T.J., Naismich, A.L., and Riordan, J.R. 1992. Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat. Genet. 1:321-327.
8. Kälin, N., Claaß, A., Sommer, M., Puchelle, E., and Tümmler, B. 1999. ΔF508 CFTR protein expression in tissues from patients which cystic fibrosis. J. Clin. Invest. 103:1379-1389.
9. Ellgaard, L., Molinari, M., and Helenius, A. 1999. Sectting the standards: Quality control in the secretory pathway. Science. 286:1882-1888.
10. Qu, B.H., Scrickland, E., and Thomas, P.J. 1997. Cystic fibrosis: A disease of altered protein folding. J. Bioenerg. Biomembr. 29:483-490.
11. Cheng, S.H., et al. 1990. Functional activation of the cystic fibrosis trafficking mutant DF508-CFTR by overexpression. Am. J. Physiol. 268:L615-L624.
12. Dalemans, W., et al. 1991. Altered chloride ion channel kinetics associated with the DF508 cystic fibrosis mutation. Nature. 354:526-528.
13. Qu, B.H., and Thomas, P.J. 1996. Alteration of the cystic fibrosis transmembrane conductance regulator folding pathway. J. Biol. Chem. 271:7261-7264.
14. Drumm, M.L., et al. 1991. Chloride conductance expressed by DF508 and other mutant CFTRs in Xenopus oocytes. Science. 254:1797-1799.
15. Haws, C.M., et al. 1996. Delta F508-CFTR channels: Kinetics, activation by forskolin, and potentiation by xanthines. Am. J. Physiol. 270:C1544-C1555.
16. Denning, G.M., et al. 1992. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature. 358:761-764.
17. Li, C., et al. 1993. The cystic fibrosis mutation (delta F508) does not influence the chloride channel activity of CFTR. Nat. Genet. 3:311-316.
18. Lukacs, G.L., et al. 1993. The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. J. Biol. Chem. 268:21592-21598.
19. Sharma, M., Benharouga, M., Hu, W., and Lukacs, G.L. 2001. Conformational and temperature-sensitive stability defects of the delta F508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments. J. Biol. Chem. 276:8942-8950.
20. Heda, G.D., Tanwani, M., and Marino, C.R. 2001. The Delta F508 mutation shortens the biochemical half-life of plasma membrane CFTR in polarized epithelial cells. Am. Physiol. Cell Physiol. 280:C166-C174.
21. Roomans, G.M. 2001. Pharmacological treatment of the ion transport defect in cystic fibrosis. Expert Opin. Investig. Drugs. 10:1-19.
22. Gekko, K., and Ito, H. 1990. Competing solvent effects of polyols and guanidine hydrochloride on protein stability. J. Biochem. (Tokyo). 107:572-577.
23. Brown, C.R., Hong-Brown, L.Q., and Welch, W.J. 1997. Strategies for correcting the delta F508 CFTR protein-folding defect. J. Bioenerg. Biomembr. 29:491-502.
24. Sato, S., Ward, C.L., Krouse, M.E., Wine, J.J., and Kopito, R.R. 1996 Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem. 271:635-638.
25. Fischer, H., et al. 2001. Partial restoration of defective chloride conductance in DeltaF508 CF mice by trimethylamine oxide. Am. J. Physiol. Lung Cell. Mol. Physiol. 281:L52-L57.
26. Morello, J.P., Petaja-Repo, U.E., Bichet, D.G., and Bouvier, M. 2000. Pharmacological chaperones: A new twist on receptor folding. Trends Pharmacol. Sci. 21:466-469.
27. Kruh, J. 1982. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell. Biochem. 42:65-82.
28. Marks, P.A., Richon, V.M., and Rifkind, R.A. 2000. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92:1210-1216.
29. Cheng, S.H., et al. 1995. Functional activation of the cystic fibrosis trafficking mutant delta F508-CFTR by overexpression. Am. J. Physiol. 268:L615-L624.
30. Rubenstein, R.C., Egan, M.E., and Zeitlin, P.L. 1997. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J. Clin. Invest. 100:2457-2465.
31. Heda, G.D., and Marino, C.R. 2000. Surface expression of the cystic fibrosis transmembrane conductance regulator mutant DeltaF508 is markedly upregulated by combination treatment with sodium butyrate and low temperature. Biochem. Biophys. Res. Commun. 271:659-664.
32. Rubenstein, R.C., and Zeitlin, P.L. 2000. Sodium 4-phenylbutyrate downregulates Hsc70: Implications for intracellular trafficking of DeltaF508-CFTR. Am. J. Physiol. Cell Physiol. 278:C259-C267.
33. Choo-Kang, L.R., and Zeitlin, P.L. 2001. Induction of HSP70 promotes DeltaF508 CFTR trafficking. Am. J. Physiol. Lung Cell. Mol. Physiol. 281:L58-L68.
34. Linsdell, P. 2001. Direct block of the cystic fibrosis transmembrane conductance regulator Cl(-) channel by butyrate and phenylbutyrate. Eur. J. Pharmacol 411:255-260.
35. Loffing, J., Moyer, B.D., Reynolds, D., and Stanton, B.A. 1999. PBA increases CFTR expression but at high doses inhibits Cl(-) secretion in Calu-3 airway epithelial cells. Am. J. Physiol. 277:L700-L708.
36. Moyer, B.D., Loffing-Cueni, D., Loffing, J., Reynolds, D., and Stanton, B.A. 1999. Butyrate increases apical membrane CFTR but reduces chloride secretion in MDCK cells. Am. J. Physiol. 277:F271-F276.
37. Loffing-Cueni, D., et al. 2001. Trafficking of GFP-tagged DeltaF508-CFTR to the plasma membrane in a polaryzed epithelial cell line. Am. J. Physiol. Cell Physiol. 281:C1889-C1897.
38. Matthews, J.B., et al. 1998. Na-K-2Cl cotransporter gene expression and Function during enterocyte differentiation. Modulation of Cl-secretory capacity by butyrate. J. Clin. Invest. 101:2072-2079.
39. Guay-Broder, C., et al. 1995. Al receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation. Biochemistry. 34:9079-9087.
40. Srivastava, M., Eidelman, O., and Pollard. H.B. 1999. Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis. Mol. Med. 5:703-767.
41. Eidelman, O., Zhang, J., Srivastava, M., and Pollard, H.B. 2001. Cystic fibrosis and the use of pharmacogenomics to determine surrogate endpoints For drug discovery. Am. J. Phamnacogenomics. 1:221-238.
42. Kaufman, R.J. 2002. Orchestrating the unfolded protein response in health and disease. J. Clin. Invest. 110:1389-1398. doi:10.1172/ JCI200216886.
43. Kopito, R.R. 2000. Aggresomes inclusion bodies and protein aggregation. Trends Cell Biol. 10:524-530.
44. Yang, Y., Janich, S., Cohn, J.A., and Wilson, J.M. 1993. The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc. Natl. Acad. Sci. USA. 90:9480-9484
45. Meacham, G.C., et al. 1999. The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J. 18:1492-1505
46. Loo, M.A., et al. 1998. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. EMBO J. 17:6879-6887.
47. Pind, S., Riordan, J.R., and Williams, D.B. 1994. Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 269:12784-12788.
48. Nadler, S.G., Tepper, M.A., Schacter. B., and Mazzucco, C.E. 1992. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science. 258:484-486.
49. Jiang, C., et al. 1998. Partial restoration of cAMP-stimulated CFTR chloride channel activity in DeltaF508 cells by deoxyspergualin. Am. Physiol. 275:C171-C178.
50. Brodsky, J.L. 1999. Selectivity of the molecular chaperone-specific immunosuppressive agent 15-deoxyspergualin: Modulation of Hsc70 ATPase activity without compromising DnaJ chaperone interactions. Biochem. Pharmarcol. 57:877-880.
51. Sittler, A., et al. 2001. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 10:1307-1315.
52. Egan, ME., et al. 2002. Calcium-pump inhibitors induce functional surface expression of DeltaF508-CFTR protein in cystic fibrosis epithelial cells. Nat. Med. 8:485-492.
53. Bertolotti, A., Zhang, Y., Hendershot, L.M., Harding, H.P., and Ron, D. 2000. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat. Cell Biol. 2:326-332.
54. McPherson, M.A., et al. 2001. The CFTR-mediated protein secretion defect: Pharmacological correction. Pflugers Arch. 443(Suppl. 1):S121-S126.
55. Dormer, R.L., et al. 2001. Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J. Cell Sci. 114:4073-4081.
56. Maitra, R., Shaw, C.M., Stanton, B.A., and Hamilton, J.W. 2001. Increased functional cell surface expression of CFTR and DeltaF508-CFTR by the anthracycline doxotubicin. Am. J. Physiol. Cell Physiol. 280:C1031-C1037.
57. Galietta, L.V., Jayaraman, S., and Verkman, A.S. 2001. Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am. J. Physiol. Cell Physiol. 281:C1734-C1742.